← All trials
NCT05618587
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Nov 16, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- State University of New York, BuffaloLead sponsor
- University at BuffaloOverall official - principal investigator
- State University of New York, BuffaloReponsible party - principal investigator
- National Center for Advancing Translational Science (NCATS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.